Literature DB >> 10609336

Oxidative stress in patients with multiple sclerosis.

C Syburra1, S Passi.   

Abstract

It is well known that brain and nervous system cells are prone to oxidative damage because of their relatively low content of antioxidants, especially enzymatic ones, and of the high levels of both membrane polyunsaturated fatty acids (PUFA) and iron easily released from injured cells. We have investigated the oxidative stress in the blood (plasma, erythrocytes and lymphocytes) of 28 patients affected with multiple sclerosis (MS) and of 30 healthy age matched controls, by performing a multiparameter analysis of non-enzymatic and enzymatic antioxidants--Vitamin E (Vit. E), ubiquinone (UBI), reduced and oxidized glutathione (GSH, GS-SG), superoxide dismutase (SOD), glutathione peroxidase (GPX), catalase (CAT) and fatty acid patterns of phospholipids (PL-FA). PL-FA and Vit. E were assayed by GC-MS; UBI and GSH/GS-SG by HPLC; SOD, GPX and CAT by spectrophotometry. In comparison to controls, patients with MS showed significantly reduced levels of plasma UBI (0.21 +/- 0.10 vs. 0.78 +/- 0.08 mg/ml, p < 0.001), plasma Vit. E (7.4 +/- 2.1 vs. 11.4 +/- 1.8 mg/ml, p < 0.01), lymphocyte UBI (8.1 +/- 4.0 vs. 30.3 +/- 7.2 ng/ml blood, p < 0.001) and erythrocyte GPX (22.6 +/- 5.7 vs. 36.3 +/- 6.4 U/g Hb, p < 0.001). This blood antioxidant deficiency was associated with plasma levels of PL-PUFA--especially C20:3 n-6 and C20:4 n-6--significantly higher than controls. In conclusion, the blood of patients with MS shows the signs of a significant oxidative stress. The possibility of counteracting it by antioxidant administration plus an appropriate diet, might represent a promising way of inhibiting the progression of the disease. Antioxidant supplements should include not only GSH repleting agents, but also Vit. E, ubiquinol, and selenium.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10609336

Source DB:  PubMed          Journal:  Ukr Biokhim Zh (1999)


  8 in total

1.  Relationship between thiol-disulphide homeostasis and visual evoked potentials in patients with multiple sclerosis.

Authors:  Gönül Vural; Şadiye Gümüşyayla; Orhan Deniz; Salim Neşelioğlu; Özcan Erel
Journal:  Neurol Sci       Date:  2018-12-01       Impact factor: 3.307

2.  Iron and the folate-vitamin B12-methylation pathway in multiple sclerosis.

Authors:  S J van Rensburg; M J Kotze; D Hon; P Haug; J Kuyler; M Hendricks; J Botha; F C V Potocnik; T Matsha; R T Erasmus
Journal:  Metab Brain Dis       Date:  2006-05-26       Impact factor: 3.584

3.  Metabolic response to glatiramer acetate therapy in multiple sclerosis patients.

Authors:  Lidia De Riccardis; Alessandra Ferramosca; Antonio Danieli; Giorgio Trianni; Vincenzo Zara; Francesca De Robertis; Michele Maffia
Journal:  BBA Clin       Date:  2016-10-18

Review 4.  Erythrocytes in multiple sclerosis - forgotten contributors to the pathophysiology?

Authors:  Kira Groen; Vicki E Maltby; Katherine A Sanders; Rodney J Scott; Lotti Tajouri; Jeannette Lechner-Scott
Journal:  Mult Scler J Exp Transl Clin       Date:  2016-05-19

5.  Neuromuscular electrical stimulation and dietary interventions to reduce oxidative stress in a secondary progressive multiple sclerosis patient leads to marked gains in function: a case report.

Authors:  David Reese; Ezzatolah T Shivapour; Terry L Wahls; Shauna D Dudley-Javoroski; Richard Shields
Journal:  Cases J       Date:  2009-08-10

6.  Nicotinic acid-mediated activation of both membrane and nuclear receptors towards therapeutic glucocorticoid mimetics for treating multiple sclerosis.

Authors:  W Todd Penberthy
Journal:  PPAR Res       Date:  2009-05-17       Impact factor: 4.964

Review 7.  Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics.

Authors:  Gerwyn Morris; Michael Maes
Journal:  BMC Med       Date:  2013-09-17       Impact factor: 8.775

Review 8.  Is Modulation of Oxidative Stress an Answer? The State of the Art of Redox Therapeutic Actions in Neurodegenerative Diseases.

Authors:  Valerio Chiurchiù; Antonio Orlacchio; Mauro Maccarrone
Journal:  Oxid Med Cell Longev       Date:  2015-12-31       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.